Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Bourdenet

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Contact Dermatitis|June 15, 2025
Infrared Radiation-Induced Urticaria: A Case ReportAngéline Charansol, V Bourdenet, Anatole Hanniet, et al.
Contact Dermatitis|February 20, 2025
Contact Dermatitis From Natural Indigo (Indigofera Tinctoria Leaf Extract) Contained in Hair Dye Preparations: A Case SeriesAngéline Charansol, V Bourdenet, Anatole Hanniet, et al.
Allergy|March 22, 2025
Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast MediaD Do, L Bertolotti, A Mosnier, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 29, 2025
Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAbG U Machado, V Bourdenet, G Devouassoux, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Contact Dermatitis|June 15, 2025
Infrared Radiation-Induced Urticaria: A Case ReportAngéline Charansol, V Bourdenet, Anatole Hanniet, et al.
Contact Dermatitis|February 20, 2025
Contact Dermatitis From Natural Indigo (Indigofera Tinctoria Leaf Extract) Contained in Hair Dye Preparations: A Case SeriesAngéline Charansol, V Bourdenet, Anatole Hanniet, et al.
Allergy|March 22, 2025
Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast MediaD Do, L Bertolotti, A Mosnier, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 29, 2025
Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAbG U Machado, V Bourdenet, G Devouassoux, et al.
Pageof 1